moxifloxacin has been researched along with Adult Spinal Muscular Atrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artero, R; Boido, M; Januel, C; Konieczny, P; Mamchaoui, K; Martinat, C; Menduti, G | 1 |
| Artero, R; Konieczny, P | 1 |
2 other study(ies) available for moxifloxacin and Adult Spinal Muscular Atrophy
| Article | Year |
|---|---|
Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model.
Topics: Animals; Disease Models, Animal; Exons; Humans; Mice; Moxifloxacin; Muscular Atrophy, Spinal; Phenotype; Survival of Motor Neuron 1 Protein | 2022 |
Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA.
Topics: Alternative Splicing; Animals; Animals, Genetically Modified; Blood-Brain Barrier; Disease Models, Animal; Drosophila melanogaster; Drug Evaluation, Preclinical; Exons; Genes, Reporter; Humans; Moxifloxacin; Muscular Atrophy, Spinal; Survival of Motor Neuron 2 Protein | 2020 |